Aripiprazole: A Review of its Use in the Treatment of Irritability Associated with Autistic Disorder Patients Aged 6-17

Journal of Central Nervous System Disease

Review

Sarah Curran¹  Victoria Bird²  Petrina Douglas-Hall³  David Taylor⁴ 

[1] Department of Child and Adolescent Psychiatry, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF;Health and Service and Population Research, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF;Pharmacy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AZ;Pharmacy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AZ;Institute of Pharmaceutical Science, King's College, London;

关键词: aripiprazole;    autism;    children;   

DOI  :  10.4137/JCNSD.S4140

来源: Sage Journals

【 摘 要 】

A systematic review and meta-analysis were performed examining the efficacy of aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents. Aripiprazole was found to be more effective in reducing irritability compared with placebo at 8 weeks, SMD -0.64 [-0.90 to -0.39, P < 0.00001] as determined by the Aberrant Behaviour Checklist irritability subscale (ABC-I). Pooled data from two eight week trials show that sedation is the most commonly reported adverse event. Statistically significant weight gain was also associated with aripiprazole, but there was a decrease in serum prolactin. Most adverse effects were deemed to be mild to moderate in severity. Four open trials and three case series all show support for aripiprazole in reducing the behavioural symptoms of autism. Long-term studies are required to determine the efficacy and safety of aripiprazole in autistic disorder in children.

【 授权许可】

CC BY-NC   
© 2011 SAGE Publications.

【 图 表 】

Figure 1.

Figure 1.

Figure 5.